Raloxifene or other selective ER modulators were not prohibited for use in approved indications, although little data are available for such agents in patients with a history of breast cancer. Bone mineral density was documented in the source documents confirming osteoporosis/osteopenia. Raloxifene is not approved for the treatment of adjuvant breast cancer and was not to be used for this purpose during a patient’s participation in the trial.